Whether you are evaluating Eco-Inject against alternatives or simply want to understand more about how our device could fit into your pipeline requirements, we're here to help.
_converted.webp)
_converted%20(1).webp)
_converted.webp)
Let us know how to contact you and some insight into your enquiry. We will get back to you soon.
A first conversation is short and practical. It usually covers your programme, your drug format and target volumes, and where the device needs to fit. You come away with a clear read on compatibility, indicative timelines, and what a formal evaluation would involve. If a pilot device would help your team assess handling, that can be arranged from here.
Device compatibility with your drug format, viscosity, and fill volume
Handling and usability, including pilot production devices for hands-on assessment
The manufacturing and supply arrangement
Sustainability data, including life-cycle assessment
Intellectual property and how it supports your drug-device combination
Commercial terms and long-term pricing
For detailed technical and commercial discussion, Eco-Inject works under a mutual NDA, and a data room can be opened for review by your team.
The device is manufactured by West Pharmaceutical Services, a global supplier of injectable drug delivery systems, and is designed for automated assembly at up to 60 devices per minute. Eco-Inject is the legal manufacturer, and for vertically integrated companies a licence-to-manufacture option is available. Supply arrangements for a specific programme are part of the commercial discussion.
It uses industry-standard pre-filled syringes and operates as a conventional two-step auto-injector, so it is designed to fit existing drug-device combination product frameworks rather than introduce a new device format. Your regulatory team leads on classification and submission; Eco-Inject provides the device-side technical information to support it.
The device takes the same standard 1ml and 2.25ml pre-filled syringes and keeps the two-step format, so the drug and the patient experience stay as they are. The change is contained to the device itself rather than the molecule or the way patients use it, which keeps the evaluation focused.
The device is patented, and that protection extends the defensibility of your drug-device combination. A detailed IP summary is shared under NDA as part of an evaluation.
Yes. Both are primary segments. Innovators typically focus on portfolio standardisation, supply security, and sustainability at pipeline scale; generic and biosimilar developers focus on cost at volume, direct engagement, and a sustainability profile that scores in tenders. The device serves both from one platform.
© 2026 Eco Inject (Pty) ltd. All Rights Reserved.
Site designed and developed by Adopter
